The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Characteristics of advanced NSCLC patients with at least 6 months erlotinib treatment duration in Czech Republic.
Helena Coupkova
No relevant relationships to disclose
Jana Skrickova
No relevant relationships to disclose
Karel Hejduk
No relevant relationships to disclose
Bortlicek Zbynek
No relevant relationships to disclose
Bohdan Kadlec
No relevant relationships to disclose
Frantisek Salajka
No relevant relationships to disclose
Milos Pesek
No relevant relationships to disclose
Vitezslav Kolek
No relevant relationships to disclose
Leona Koubkova
No relevant relationships to disclose
Dimka Sixtova
No relevant relationships to disclose
Petr Zatloukal
No relevant relationships to disclose
Jaromir Roubec
No relevant relationships to disclose
Milada Zemanova
No relevant relationships to disclose
Rostislav Vyzula
No relevant relationships to disclose
Stanislav Spelda
No relevant relationships to disclose